Neopuntia Brochure

Premium Nutraceuticals
The healthy
lipophilic fiber
Patented cactus powder
upports healthy weight
S
management
Helps to regulate blood lipids
(Metabolic syndrome study)
Premium
ingredient
Organic
Clinically
tested
The healthy lipophilic fiber
NeOpuntia® interacts with ingested fat
Pourcentage of the control
• NeOpuntia® reduces fat bioavailability by 28%
• NeOpuntia® performs better than chitosan
• NeOpuntia® increases amount of fecal fat
100
Bioavailability of fat
NeOpuntia® is a patented complex of insoluble and soluble
dietary fibers. In vitro(1) and pilot clinical works(2) demonstrate
that the physical interaction between NeOpuntia® and fat helps
to reduce fat absorption:
120
The last clinical study(3) highlighted that NeOpuntia® could
positively influence Syndrome X diagnosis thanks to its beneficial
effect on the management of associated risk factors:
• With NeOpuntia®, 39% of women no longer
diagnosed for syndrome X at the end of the
study.
60
40
20
Control
Branded Chitosan
NeOpuntia®
Clinical study on NeOpuntia® - Evolution of HDL level
0,04
+ 0,0217 g/l
g/l
0,02
0,00
-0,02
• decrease LDL cholesterol level
• increase HDL cholesterol level
• reduce triglycerides level
NeOpuntia® and Syndrome X
-28%
80
0
Blood lipid regulation
A published clinical study(3) showed that NeOpuntia® had
positive effects on balancing blood lipid levels. Associated with a
well-balanced diet 1.6 g of NeOpuntia® per meal helps to:
Reduction of fat bioavailability
thanks to NeOpuntia® _ In vitro test
-0,04
-0,06
- 0,047 g/l
Placebo
NeOpuntia®
Women diagnosed free
of Metabolic Syndrome at the end of study
40 %
39%
30 %
20 %
10 %
8%
0%
Placebo
NeOpuntia®
A PATENTED HEALTHY FIBER
• 100 % green, natural, organic & kosher
• Patented lipophilic activity
(1)
In vitro simulation of GI track assessing the bio-accessibility of fat when
ingested with a 2g dose of NeOpuntia® (works of 2001, 2004 and 2005).
• Extensive and published scientific works
(2)
NeOpuntia® and fat binding. Double blind, placebo-controlled pilot
clinical study run in 2003.
• Active dose: 1.6 g after a heavy meal
E. Linares. The effect of NeOpuntia® on blood Lipid parameters - risk
factors for the Metabolic Syndrome (Syndrome X). Advances in Therapy®,
vol. 24 N°5; September-October 2007.
(3)
NEXIRA - 129 chemin de Croisset - BP 4151 - 76723 Rouen cedex 3 - FRANCE
Tel : +33 (0)2 32 83 18 18 - Fax : +33 (0)2 32 83 19 19 - [email protected] - www.nexira.com